SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description

   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Speaker
Icilma V. Fergus, MD, FACC
Director Cardiovascular Disparities
Associate Professor of Medicine
Mount Sinai School of Medicine
New York, NY


Moderator and Course Director
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH
Professor of Medicine
Tulane University School of Medicine
Tulane Heart and Vascular Institute
New Orleans, LA

Title
: Recognizing and Managing hATTR Cardiac Amyloidosis: Bridging Evidence and Clinical Practice
Activity/Course #:
: NCME357
Cost:
: Free
Release/Start Date:
: Oct 15 2018
Expiration Date:
: Oct 14 2019
Topics:
: Cardiovascular
Target Audience:
: Cardiologists, Primary Care Physicians, Nurse Practitioners, Physician Assistants, and other clinicians that care for patients with cardiovascular disease
Format:
: Webcast
Estimated Time To Complete CME Activity:
: 1.25 Hours
Credit(s):
: 1.25 AMA PRA Category I Credit(s)
1.25 AANP Contact hour(s) which includes 0.25 pharmacology hour(s)
Hardware/Software Requirements:

Program Summary:

Amyloidoses are a heterogeneous group of disorders with a variety of clinical presentations characterized by tissue deposition of insoluble, misassembled fibril proteins (amyloid) that disrupt normal tissue structure and function. Amyloidosis involving the heart (cardiac amyloidosis) was once thought to be a rare disease but is increasingly recognized due to enhanced clinical awareness and better diagnostic imaging. Early recognition is important because more effective treatment strategies have become available and new therapies are emerging. However, amyloidosis may present in a wide variety of ways, posing challenges to its diagnosis and treatment.

This activity will address the different types of cardiac amyloidosis, the clinical manifestations of hATTR amyloidosis, and present treatment strategies based on the most recent clinical data.

This webcast was recorded live at the Conversations in Cardiology 2018 Live Virtual Broadcast and is being used with the permission of the presenters.

Learning Objectives

After completing this program participants should be able to:

  1. Describe the different types of cardiac amyloidosis
  2. Recognize the clinical manifestations of hATTR amyloidosis
  3. Implement current strategies for the diagnosis of hATTR amyloidosis
  4. Utilize the most recent clinical evidence to inform decisions about treatment of hATTR amyloidosis

How to obtain the CME Certificate

  1. Register for the course at www.naceonline.com.
  2. View the content.
  3. Complete and submit the post-test and evaluation.
  4. A minimum passing score of 60% must be earned on the post-test in order to complete the CME activity.
  5. Print your CME certificate.
Sponsored and Certified By
National Association for Continuing Education & Association of Black Cardiologists, Inc.
Accreditation Designation Statement
The Association of Black Cardiologists, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Association of Black Cardiologists, Inc. designates this enduring activity for a maximum of 1.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 1.25 contact hour of continuing education which includes 0.25 pharmacology hours.
Faculty Disclosure Policy
Policy on Faculty and Provider Disclosure: It is the policy of the accredited provider to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the National Association for Continuing Education are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosures are provided below.

Speaker
Icilma V. Fergus has no relationships to disclose.

Course Director and Moderator
Keith C. Ferdinand, MD, FACC, FAHA, FNLA, FASH is a consultant for Amgen, Boehringer Ingelheim, Sanofi, Novartis, Quantum Genomics, Janssen.

Activity Planning Committee
Josh Kilbridge, Medical Writer, has no relationship to disclose.

Gregg Sherman, MD, has no relationships to disclose.

Harvey C. Parker, Ph.D., has no relationships to disclose.

Michelle Frisch, MPH, has no relationships to disclose.

Sheila Lucas, CWEP, has no relationships to disclose.

Sandy Bihlmeyer, MEd, has no relationship to disclose.

Alan Goodstat, LCSW, has no relationships to disclose.
Commercial Support
This educational activity is supported by an educational grant from Alnylam Pharmaceuticals, Inc.